Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2013 /
Comparing toxicity profiles for 72 hour infusional and conventional bleomycin in testicular cancer

3rd - 6th Nov 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.11.13
Views: 4514

Dr Jonathan Shamash - Barts Cancer Institute, London, UK

Dr Shamash talks to ecancertv at the UK's National Cancer Research Institute ( NCRI ) 2013 meeting about a randomised trial of 72 hour infusional bleomycin in BEP (cisplatin, etoposide  and bleomycin) versus conventional weekly bleomycin in patients with metastatic tesicular cancer; sepcifically IGCCCG good prognosis disease.

The trial came up negative for a decrease in toxicity in the new treatment arm, but the data had some interesting implications such as unless theres a very good reason, all plateints should be ofered bleomycin in the original therapy, though treatment should be stopped early if lung damage starts to appear on CT scans in the first 3 weeks.

A dry cough was also found to be a warning to stop the treatment and CT scan early.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation